{
  "schema_version": "0.4",
  "ir_kind": "hl",
  "metadata": {
    "title": "Morphogen Treatment Panel Application",
    "source": {
      "type": "paper",
      "id": "s41592-025-02927-5"
    }
  },
  "resources": {
    "materials": [
      {
        "id": "organoid_material",
        "name": "Developing organoids"
      },
      {
        "id": "chir_material",
        "name": "CHIR99021 (CHIR, WNT pathway activator)"
      },
      {
        "id": "xav_material",
        "name": "XAV939 (WNT pathway inhibitor)"
      },
      {
        "id": "shh_material",
        "name": "rh‑SHH/CS24II (SHH)"
      },
      {
        "id": "purmorphamine_material",
        "name": "purmorphamine"
      },
      {
        "id": "fgf8_material",
        "name": "FGF‑8B (FGF8)"
      },
      {
        "id": "ra_material",
        "name": "RA"
      },
      {
        "id": "bmp4_material",
        "name": "rhBMP‑4 (BMP4)"
      },
      {
        "id": "bmp7_material",
        "name": "rhBMP‑7 (BMP7)"
      }
    ],
    "containers": [
      {
        "id": "culture_plate",
        "name": "culture plate"
      }
    ],
    "equipment": [
      {
        "id": "incubator",
        "name": "incubator"
      }
    ],
    "samples": [
      {
        "id": "organoid_sample",
        "name": "organoid_sample"
      }
    ],
    "data": []
  },
  "protocol": {
    "steps": [
      {
        "id": "s1",
        "op": "allocate",
        "inputs": [],
        "outputs": [
          {
            "kind": "sample",
            "id": "organoid_sample"
          }
        ],
        "params": {
          "material_ref": "organoid_material"
        },
        "annotations": {}
      },
      {
        "id": "s2",
        "op": "annotate",
        "inputs": [
          {
            "kind": "sample",
            "id": "organoid_sample"
          }
        ],
        "outputs": [
          {
            "kind": "sample",
            "id": "organoid_sample"
          }
        ],
        "params": {},
        "annotations": {
          "note": "Developing organoids were then subjected to a panel of morphogen treatments with varying timing, concentration and combination of the molecules CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh‑SHH/CS24II (SHH) and purmorphamine, FGF‑8B (FGF8), RA, rhBMP‑4 (BMP4), rhBMP‑7 (BMP7) at early and intermediate time points (days 0–3, 10–13 and 14–17)."
        }
      }
    ],
    "start_step_id": "s1",
    "edges": [
      {
        "from": "s1",
        "to": "s2"
      }
    ],
    "detail_level": 0
  }
}